# Zai Lab Limited (ZLAB) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ZLAB
## Company Profile
- Ticker: ZLAB
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biopharma, Diagnostics, Life Science Tools, Oncology, CNS
## Stock Data
- Close: 20.2 USD
- Market cap: 2313782967.54 USD
- Last updated: 2026-07-17
## Business Overview
Zai Lab Limited is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
## Why The Stock Is Moving

ZLAB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Zai Lab Limited is followed within the diagnostics and tools universe for its exposure to customer demand and adoption cycles.

## Business Model

Zai Lab Limited is a commercial-tools story where install base, recurring demand, and product adoption drive the narrative more than one-off clinical events.

## Landscape Position

Compared with therapeutic biotech names, Zai Lab Limited sits on a different part of the landscape where utilization, customer demand, and product refresh tend to matter more than binary FDA events.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.